Vertex Pharmaceuticals and CRISPR Therapeutics project that revenues from Casgevy, a gene therapy for sickle cell disease and beta thalassemia, will nearly triple by 2026 as patient access improves. This ambitious goal follows a year of slow uptake for the therapy.
Following over a year of slow uptake, Vertex Pharmaceuticals and CRISPR Therapeutics expect Casgevy revenues to nearly triple in 2026, as patient access to the sickle cell disease and beta thalassemia gene therapy grows.
Original title: “Vertex, CRISPR Set Lofty Goal for Casgevy Gene Therapy as Patient Starts Ramp”